Bourlon CRA, Quiróz CÓ, Bourlon RC, Vera UR, Contreras ZK

Language: Spanish
References: 28
Page: 210-216
PDF size: 265.16 Kb.

ABSTRACT

Nephrogenic systemic fibrosis is a new disease that is characterized by tissue fibrosis in patients with impaired renal function. Is associated with prior exposure to contrast medium with gadolíneo magnetic resonance studies. The progression of the disease may affect death. It is important that health staff are aware of the possibility of this disease in patients with risk factors.

REFERENCES

1. Issa N, Poggio ED, Fatica RA, Patel R, et al. Nephrogenic systemic fibrosis and its association with gadolinium exposure during MRI. Cleveland Clinic Journal of Medicine 2008;75(2):95-111.

2. Cowper SE, Robin HS, Steinberg SM, Su LD, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000;356:1000-1.

3. Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004;50:2660.

4. Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 2006;18:614.

5. Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadoliniumbased MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007;242:647.

6. Cowper SE, Bucala R, Leboit PE. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis-setting the record straight. Semin Arthritis Rheum 2006;35:208.

7. The International Center for Nephrogenic Fibrosing Dermopathy Research. http://www.icnfdr.org (Accessed January, 2008).

8. LeBoit PE. What nephrogenic fibrosing dermopathy might be. Arch Dermatol 2003;139:928.

9. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243:148.

10. Moschella SL, Kay J, Mackool BT, Liu V. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 35-2004. A 68-year-old man with end-stage renal disease and thickening of the skin. N Engl J Med 2004;351:2219.

11. Cowper SE, Bucala R, LeBoit PE. Case 35-2004: nephrogenic fibrosing dermopathy. N Engl J Med 2005;352:1723.

12. Mendoza FA, Artlett CM, Sandorfi N, et al. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006;35:238.

13. Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents St. Louis, Missouri, 2002-2006. MMWR 2007;56:137.

14. High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:21.

15. High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007;56:710.

16. Perazella MA, Rodby RA. Gadolinium use in patients with kidney disease: A cause for concern. Semin Dial 2007;20:1.

17. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: A population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007;2:264.

18. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998;5:491.

19. Saitoh T, Hayasaka K, Tanaka Y, et al. Dialyzability of gadodiamide in hemodialysis patients. Radiat Med 2006;24:445.

20. Broome DR, Girguis MS, Baron PW, et al. Gadodiamide- associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007;188:586.

21. Cowper SE, Su LD, Bhawan J, et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001;23:383.

22. Edsall LC, English JC, Teague MW, Patterson JW. Calciphylaxis and metastatic calcification associated with nephrogenic fibrosing dermopathy. J Cutan Pathol 2004;31:247.

23. Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 2006; 18:614–617.

24. Levine JM, Taylor RA, Elman LB, et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve 2004;30:569.

25. Maloo M, Abt P, Kashyap R, et al. Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant 2006;6:2212.

26. Fisher GJ, Datta S, Wang Z, et al. c-Jun-dependent inhibition of cutaneous procollagen transcription following ultraviolet irradiation is reversed by all-trans retinoic acid. J Clin Invest 2000; 106:663.

27. http://www.fda.gov/cder/drug/advisory/gadolinium_agents.htm

28. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359.